Log in

Relevant bibliographies by topics / 332.74 (477-25) (043.2)

Contents

Journal articles

Academic literature on the topic '332.74 (477-25) (043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '332.74 (477-25) (043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "332.74 (477-25) (043.2)"

1

Adinolfi, A., S. Sirotti, G. Sakellariou, et al. "POS1141 ASSESSING RELEVANT JOINTS FOR MONITORING CPPD DISEASE: A SYSTEMATIC LITERATURE REVIEW OF IMAGING TECHNIQUES BY THE OMERACT ULTRASOUND – CPPD SUBGROUP." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 850.1–850. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3153.

Full text

Abstract:

Background:Imaging has been extensively used for the Calcium Pyrophosphate Deposition Disease (CPPD) diagnosis but the prevalence of joint calcifications at imaging in CPPD patients has not been thoroughly assessed.Objectives:This systematic literature review (SLR) is aimed to estimate the prevalence of calcium crystal deposition in peripheral joints by imaging in suspected or definite CPPD patients to establish relevant joints for CPPD monitoringMethods:After defining PICOs, Pubmed and Embase were searched from inception to October 2020 for identifying studies that evaluated the use of Conven

APA, Harvard, Vancouver, ISO, and other styles

2

Reeder, C. B., T. E. Witzig, P. L. Zinzani, et al. "Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003)." Journal of Clinical Oncology 27, no. 15_suppl (2009): 8569. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.8569.

Full text

Abstract:

8569 Introduction: Relapsed or refractory MCL patients demonstrated a promising overall response rate (ORR) of 53% with a median duration of response (DR) of 13.7 months to single-agent lenalidomide when analyzed as a subset in a recent a phase II study (NHL-002). A supporting international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed or refractory aggressive NHL. In this report, we analyze the current results from the MCL patients enrolled in this trial. Methods: Patients with relapsed or refractory MCL and measurable disease 2 cm after at lea

APA, Harvard, Vancouver, ISO, and other styles

3

Tsuji, H., R. Nakashima, T. Sasai, et al. "POS0142 THE ASSOCIATION OF AUTOANTIBODIES WITH CLINICAL MANIFESTATIONS AND LONG-TERM REMISSIONS IN COMPARISON WITH JUVENILE- AND ADULT-ONSET IDIOPATHIC INFLAMMATORY MYOPATHIES." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 291–92. http://dx.doi.org/10.1136/annrheumdis-2023-eular.323.

Full text

Abstract:

BackgroundThe associations of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) with clinical features and remission in idiopathic inflammatory myopathy (IIM) are different between those of juvenile-onset (JIIM) and adult-onset.ObjectivesSince the associations in JIIM had not been fully elucidated, we analyzed them comparing that in adults using clinical information and autoantibodies.MethodsA total of 320 cases of IIMs (juvenile-onset, 2004-2021, n=34; adult-onset, 2018-2021, n=286) with a history of attendance at our hospital were retrospectively analyzed

APA, Harvard, Vancouver, ISO, and other styles

4

Liao, Wei, Matthew Paul Smeltzer, Jordan Goss, et al. "Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta." Journal of Clinical Oncology 43, no. 16_suppl (2025): 8002. https://doi.org/10.1200/jco.2025.43.16_suppl.8002.

Full text

Abstract:

8002 Background: The LCDR in the CT screened cohort in the National Lung Screening Trial (NLST) was 1.1% over a median of 6.5 years follow up. We evaluated the LCDR in a regional US community. Methods: Prospective cohort study of patients in LCS and IPN programs in 22 facilities across a 125 county service area population. We compared LCDR over 3 years in LCS stratified by Lung-RADS (L-R) score (1 to 4X), IPN by nodule size (≤6, >6-15, >15-20, >20-30 mm) on initial CT scans. Comparisons used Chi-square tests, Wilcoxon tests, and Cox regression models with Hazard Ratios (HR) for lung c

APA, Harvard, Vancouver, ISO, and other styles

5

Khoo, Joan, Christoph E. Hagemeyer, Darren C. Henstridge, et al. "Effects of water stably-enriched with oxygen as a novel method of tissue oxygenation on mitochondrial function, and as adjuvant therapy for type 2 diabetes in a randomized placebo-controlled trial." PLOS ONE 16, no. 7 (2021): e0254619. http://dx.doi.org/10.1371/journal.pone.0254619.

Full text

Abstract:

Background Diabetes mellitus is associated with inadequate delivery of oxygen to tissues. Cellular hypoxia is associated with mitochondrial dysfunction which increases oxidative stress and hyperglycaemia. Hyperbaric oxygenation therapy, which was shown to improve insulin sensitivity, is impractical for regular use. We evaluated the effects of water which is stably-enriched with oxygen (ELO water) to increase arterial blood oxygen levels, on mitochondrial function in the presence of normal- or high-glucose environments, and as glucose-lowering therapy in humans. Methods We compared arterial blo

APA, Harvard, Vancouver, ISO, and other styles

6

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Full text

Abstract:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

APA, Harvard, Vancouver, ISO, and other styles

7

Rashidzadeh, Hamid, Mahsa Salimi, Somayeh Sadighian, Kobra Rostamizadeh, and Ali Ramazani. "In vivo Antiplasmodial Activity of Curcumin-Loaded Nanostructured Lipid Carriers." Current Drug Delivery 16, no. 10 (2019): 923–30. http://dx.doi.org/10.2174/1567201816666191029121036.

Full text

Abstract:

Background: It was shown that curcumin (Cur) has anti-plasmodium activity, however, its weak bioavailability, rapid metabolism, and limited chemical stability has restricted its application in clinical usages. Nanostructured lipid carriers (NLCs) are a type of drug-delivery systems (DDSs) which their core matrix is composed of both solid and liquid lipids. Objective: The aim of the current study was to prepare and characterize curcumin-loaded nanostructured lipid carriers (Cur-NLC) for malaria treatment. Methods: For the production of NLC, coconut oil and cetyl palmitate were selected as a liq

APA, Harvard, Vancouver, ISO, and other styles

8

Kloner, Robert A., Coleman Gross, Jinwei Yuan, Ansgar Conrad, and Pablo E. Pergola. "Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors." Journal of Cardiovascular Pharmacology and Therapeutics 23, no. 6 (2018): 524–31. http://dx.doi.org/10.1177/1074248418788334.

Full text

Abstract:

Introduction: Hyperkalemia (potassium >5.0 mEq/L) affects heart failure patients with renal disease regardless of the use of renin–angiotensin–aldosterone system inhibitors (RAASi). The open-label TOURMALINE study showed that patiromer, a sodium-free, nonabsorbed potassium binder, lowers serum potassium of hyperkalemic patients similarly when given with or without food; unlike prior studies, patients were not required to be taking RAASi. We conducted post hoc analyses to provide the first report of patiromer in patients not taking RAASi. Methods: Hyperkalemic patients received patiromer, 8.

APA, Harvard, Vancouver, ISO, and other styles

9

Trentin, F., C. Tani, A. Cauli, et al. "AB0558 ANIFROLUMAB IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE, MULTICENTER STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1476. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3552.

Full text

Abstract:

BackgroundAnifrolumab (ANI) is a monoclonal antibody to the type I interferon receptor recently approved by EMA as an add-on therapy for the treatment of moderate to severe SLE. As of this writing, real world data on its use are still lacking.ObjectivesTo depict the clinical phenotype of refractory SLE patients treated with ANI. To evaluate short-term effectiveness and safety of ANI in clinical practice.MethodsMulticenter prospective cohort study on adult patients with SLE treated with ANI for compassionate use. Demographic data, clinical and treatment history, and SLICC Damage Index (SDI) wer

APA, Harvard, Vancouver, ISO, and other styles

10

Abou Alaiwi, Sarah, Dylan J. Martini, Wanling Xie, et al. "Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC)." Journal of Clinical Oncology 37, no. 7_suppl (2019): 652. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.652.

Full text

Abstract:

652 Background: CPI can induce a range of irAEs with various degrees of severity. Clinical experience with retreatment following clinically significant irAEs is growing. Methods: We retrospectively reviewed mRCC patients treated with CPI-based regimens who had >1 week therapy delay for irAEs at Dana Farber and Emory to characterize the safety and outcomes of retreatment. Toxicity was graded by CTCAEv5. Patients were divided into retreatment (R) and discontinuation (D) cohorts. Patient characteristics were compared by Fisher’s exact test or Wilcoxon’s rank sum test. ORR, OS and PFS were asse

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!